The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
1
|
M | Musculo-skeletal system | |
2
|
M09 | Other drugs for disorders of the musculo-skeletal system | |
3
|
M09A | Other drugs for disorders of the musculo-skeletal system | |
4
|
M09AX | Other drugs for disorders of the musculo-skeletal system | |
5
|
M09AX11 |
| Active Ingredient |
|---|
|
In patients with fibrodysplasia ossificans progressiva (FOP), abnormal bone formation, including heterotrophic ossification (HO), is driven by a gain-of-function mutation in the bone morphogenetic protein (BMP) type I receptor ALK2 (ACVR1). Palovarotene is an orally bioavailable retinoic acid receptor agonist, with particular selectivity at the gamma subtype of RAR. Through binding to RARγ, palovarotene decreases the BMP/ALK2 downstream signaling pathway by inhibiting the phosphorylation of SMAD1/5/8, which reduces ALK2/SMAD-dependent chondrogenesis and osteocyte differentiation resulting in reduced endochondral bone formation. |
| Document | Type | Information Source | |
|---|---|---|---|
| SOHONOS Capsule | MPI, US: SPL/PLR |